Abstract 366P
Background
Microbiome has been proposed as a promising prognostic biomarker in various types of cancer. Although recent microbiome studies have linked the bacterial microbiome in the oral cavity and nasopharynx to the prognosis of nasopharyngeal carcinoma (NPC), the clinical significance of oral mycobiome, another key player of the oral microbiome, in NPC survival remain unknown.
Methods
We enrolled 476 untreated incident NPC patients from Wuzhou, southern China during March 2010 and December 2013, with follow-up through December 2018. We collected saliva samples at the time of diagnosis and characterized the oral mycobiome using fungal internal transcribed spacer (ITS)-2 sequencing. We analyzed the relationship between oral mycobiome and the overall survival using Cox regression adjusting for multiple confounders.
Results
Overall, the average follow-up of the NPC patients [mean (SD) age, 48.5 (10.7) years; 72% male) was 5.26 years. Patients with lower oral fungal alpha diversity (measured by observed features) had an inferior 5-year overall survival rate (lower group vs. higher group = 54.9% vs. 69.6%, P for log-rank test = 0.007). We found that lower alpha diversity was associated with an increased mortality [lower vs. higher: observed features (fully adjusted hazard ratio [HR] = 1.56, 95% confidence interval [CI] = 1.08-2.25); Simpson diversity (1.50, 1.04-2.15); Shannon diversity (1.79, 1.25-2.56)]. The associations were attenuated when further adjusted for cancer stage at diagnosis, and the significant associations were found only among localized-tumor-stage patients.
Conclusions
Oral mycobiome is a potential prognostic biomarker for patients with NPC and might provide potential guidance for treatment decision.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The original field work was supported by a grant from the National Cancer Institute at the US National Institutes of Health (grant number: R01 CA115873). This work was supported by the Swedish Research Council (grant numbers: 2015-02625, 2015-06268, 2017-05814, 2019-01429), and the High-level Talents Research Start-up Project of Fujian Medical University (grant numbers: XRCZX2017035 and XRCZX2020034), the National Natural Science Foundation of China (grant number: U22A20322). Yufeng Chen was also partly supported by a scholarship from China Scholarship Council (grant number: 201600160071).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract